Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Next Previous
Trial Profile

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2018

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 18 May 2018 New trial record
    • 08 May 2018 Results of a retrospective analysis of two randomised trials (WV16240 and WV19432; n=131) assessing the predictors of Peginterferon Alfa-2a (40KD) response, published in the Journal of Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top